ProfileGDS5678 / 1434188_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 68% 68% 71% 65% 73% 69% 68% 72% 71% 68% 66% 69% 68% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2183168
GSM967853U87-EV human glioblastoma xenograft - Control 24.1278568
GSM967854U87-EV human glioblastoma xenograft - Control 34.4706671
GSM967855U87-EV human glioblastoma xenograft - Control 43.9241765
GSM967856U87-EV human glioblastoma xenograft - Control 54.684173
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2500269
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2109868
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.5439772
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.5151671
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1615368
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0139966
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2807269
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1688468
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1792168